STLP3 Antibody

What is STEAP3 and why is it important in research?

STEAP3 is a metalloreductase family member that functions as a NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce Fe(3+) chelates bound on the other side . It plays crucial roles in:

• Iron metabolism and transferrin-dependent iron uptake in erythroid cells

• Apoptosis and cell cycle progression pathways downstream of p53/TP53

• Exosome secretion by facilitating the secretion of proteins such as TCTP

• Multiple cancer progression pathways, particularly in glioblastoma, hepatocellular carcinoma, and prostate cancer

For researchers, STEAP3 is significant as both a functional study target and a potential biomarker for cancer prognosis and tumor microenvironment assessment.

What types of STEAP3 antibodies are available for research applications?

Several types of STEAP3 antibodies are available for research:

When selecting an antibody, consider its validation status and compatibility with your specific application and sample origin. Most commercially available antibodies have been tested for Western blot applications, with fewer validated for immunohistochemistry, flow cytometry, or other techniques.

How should I validate a STEAP3 antibody before using it in my experiments?

A thorough validation approach includes:

• Positive and negative controls: Use tissues known to express STEAP3 (liver, hematopoietic tissues) as positive controls . For negative controls, consider using STEAP3 knockout models or siRNA-treated samples.

• Specificity testing:

  • Western blot analysis to confirm the antibody detects a band of the expected molecular weight (~50-55 kDa)

  • Testing with blocking peptides like PEP-0523 (for antibodies such as PA5-20406)

  • Cross-reactivity assessment with other STEAP family members

• Functional validation: Verify the antibody's ability to detect changes in STEAP3 expression in response to treatments that are known to alter STEAP3 levels, such as p53 activation .

• Application-specific validation: For example, if planning to use the antibody for immunoprecipitation, validate it specifically for this purpose rather than assuming western blot validation transfers to other applications.

How can I detect STEAP3 in subcellular compartments, particularly nuclear localization?

STEAP3's subcellular localization is significant, as it can be found in both membrane-bound and nuclear forms with distinct functions . To properly detect subcellular localization:

• Cellular fractionation protocol:

  • Separate nuclear, cytoplasmic, and membrane fractions using differential centrifugation and detergent-based extraction methods

  • Validate fraction purity using markers like GAPDH (cytoplasmic), Na+/K+ ATPase (membrane), and Lamin B1 (nuclear)

• Immunofluorescence approach:

  • Fix cells using 4% paraformaldehyde (10 minutes at room temperature)

  • Permeabilize with 0.1% Triton X-100

  • Block with 5% BSA

  • Incubate with anti-STEAP3 antibody (optimal dilution determined empirically)

  • Use nuclear counterstain (DAPI) and membrane markers for colocalization studies

• Analysis considerations:

  • Quantify the nuclear/cytoplasmic ratio of STEAP3 signal

  • Compare with known conditions that affect STEAP3 localization (e.g., p53 activation, iron depletion)

Research has shown that aberrant nuclear expression of STEAP3 is associated with hepatocellular carcinoma progression through interaction with EGFR and enhancement of EGFR-RAC1-ERK-STAT3 signaling .

What are the recommended protocols for using STEAP3 antibodies in flow cytometry?

Flow cytometry with STEAP3 antibodies requires careful optimization:

• Sample preparation:

  • For surface expression: Use gentler fixation (1-2% paraformaldehyde)

  • For intracellular detection: Fix with 4% paraformaldehyde followed by permeabilization with 0.1% saponin or commercial permeabilization buffers

• Staining protocol:

  • Titrate antibody concentrations (typically 0.5-5μg per million cells)

  • Include appropriate isotype controls

  • For multicolor panels, place STEAP3 antibodies on channels with sufficient sensitivity based on expression level

• Panel design considerations:

  • For low-density expression, avoid using dimmer fluorochromes like Pacific Orange

  • When using 9+ colors, consider spectral overlap and compensation requirements carefully

  • STEAP3 detection may require level three multicolor analysis depending on expression levels and panel complexity

• Controls and validation:

  • Run fluorescence-minus-one (FMO) controls

  • Validate with STEAP3-overexpressing and knockdown cells

  • Consider using compensation beads to ensure proper compensation between channels

How do I design experiments to study STEAP3 interactions with signaling pathways?

When investigating STEAP3's role in signaling pathways:

• Co-immunoprecipitation approach:

  • Use anti-STEAP3 antibody for pull-down experiments followed by western blotting for potential interacting proteins (e.g., EGFR, RAC1, STAT3)

  • Perform reciprocal co-IP with antibodies against suspected binding partners

  • Include appropriate controls (IgG control, input samples)

• Signaling pathway analysis:

  • After STEAP3 manipulation (overexpression or knockdown), assess phosphorylation status of downstream effectors:

    • For RAC1-ERK-STAT3 pathway: measure phospho-ERK1/2 (Thr202/Tyr204) and phospho-STAT3 (Tyr705)

    • For JAK-STAT pathway: measure phospho-JAK2 and phospho-STAT3

  • Use specific pathway inhibitors to confirm STEAP3-dependent effects

• Temporal dynamics:

  • Perform time-course experiments after STEAP3 manipulation to determine sequence of pathway activation events

  • Consider using phospho-specific antibodies in parallel with total protein antibodies

• Functional readouts:

  • Measure transcriptional activity using reporter assays for STAT3 or other transcription factors

  • Assess biological outcomes (proliferation, apoptosis, migration) to connect signaling to phenotype

How can I develop isoform-specific antibodies to distinguish between STEAP3 splice variants?

Developing isoform-specific antibodies requires:

• Epitope selection strategy:

  • Identify unique amino acid sequences in each STEAP3 isoform

  • Design peptides containing these unique regions (7-20 amino acids)

  • Ensure peptides have appropriate solubility and immunogenicity

• Production approach:

  • Use a strategy similar to the STAT3β-specific antibody development that targeted the unique C-terminal 7 amino acids (FIDAVWK)

  • Consider designing immunizing peptides with additional amino acids for stability (e.g., DEPKGFIDAVWK)

  • Perform ELISA screening against both the target isoform and other isoforms to confirm specificity

• Validation requirements:

  • Test against cells overexpressing individual isoforms

  • Confirm lack of cross-reactivity with other isoforms using western blot

  • Perform immunoprecipitation followed by mass spectrometry to confirm capture of specific isoform

• Computational design considerations:

  • Consider using AI-based approaches to optimize antibody design and specificity

  • Incorporate biophysics-informed modeling to predict binding characteristics

  • Test multiple candidate sequences to identify optimal specificity profiles

What are the considerations for using STEAP3 antibodies in studying tumor microenvironment interactions?

STEAP3 has been implicated in regulating the tumor microenvironment (TME) . When designing experiments to study these interactions:

• Multi-parameter analysis approach:

  • Design flow cytometry panels that include STEAP3 along with markers for:

    • Immune cell subsets (CD3, CD4, CD8, CD11b, CD14, etc.)

    • Polarization markers (e.g., M1/M2 macrophage markers)

    • Activation status markers

  • Consider mass cytometry (CyTOF) for higher parameter analysis

• Spatial context preservation:

  • Use multiplex immunofluorescence or immunohistochemistry to maintain spatial information

  • Include markers for tumor cells, immune cells, and stromal components

  • Analyze co-localization patterns of STEAP3 with immune cell markers

• Functional assays:

  • Co-culture systems with STEAP3-manipulated tumor cells and immune cells

  • Measurement of cytokine production, immune cell activation, and migration

  • Assessment of M2 macrophage recruitment and polarization, which has been linked to STEAP3 expression

• Data integration approaches:

  • Correlate STEAP3 expression with immune scores from algorithms like ESTIMATE, ImmuneScore, and StromalScore

  • Assess relationships between STEAP3 expression and response to immunotherapy using metrics like immunophenoscore (IPS) and tumor immune dysfunction and exclusion (TIDE) score

How can I resolve contradictory STEAP3 functional data between different cancer types?

STEAP3 shows paradoxical roles across different cancer types, acting as both tumor suppressor and promoter . To resolve these contradictions:

• Context-dependent analysis framework:

  • Design experiments that compare STEAP3 function across multiple cell lines from different tissue origins

  • Manipulate STEAP3 expression identically across these models to enable direct comparison

  • Assess both phenotypic outcomes and molecular mechanisms

• Subcellular localization focus:

  • Determine if STEAP3's function correlates with its subcellular distribution

  • In HCC, nuclear STEAP3 promotes proliferation via EGFR-RAC1-ERK-STAT3 signaling

  • In other contexts, membrane-bound STEAP3 may have different functions

• Pathway analysis approach:

  • Compare pathway activation patterns following STEAP3 manipulation across different models

  • Focus on:

    • JAK-STAT signaling pathway

    • p53-mediated apoptosis pathways

    • RAC1-ERK-STAT3 axis

    • SCAP-SREBP-1 signaling for fatty acid regulation

• Experimental validation of dual function:

  • Generate domain-specific mutations to separate different functions

  • Create chimeric proteins to swap domains between STEAP3 and related proteins

  • Perform rescue experiments with specific pathway inhibitors to identify critical mediators

What are common pitfalls when using STEAP3 antibodies and how can I avoid them?

Researchers should be aware of these common issues:

• Non-specific binding solutions:

  • Increase blocking time and concentration (5% BSA or 5% non-fat milk)

  • Optimize antibody dilution through careful titration

  • Consider using blocking peptides like PEP-0523 for antibodies where available

  • Include appropriate negative controls (STEAP3 knockdown or knockout samples)

• Membrane protein extraction challenges:

  • Use specialized membrane protein extraction buffers containing appropriate detergents

  • Avoid excessive heating which can cause protein aggregation

  • Consider using lower percentage gels (8-10%) for better separation

  • Include reducing agents in sample buffers to prevent disulfide bond formation

• Cross-reactivity with other STEAP family members:

  • Validate antibody specificity against recombinant STEAP1, STEAP2, and STEAP4

  • Consider using cells with selective knockdown of individual STEAP family members as controls

  • Sequence-compare the epitope region across all STEAP family members to predict potential cross-reactivity

• Fixation-sensitive epitopes:

  • Test multiple fixation methods if standard methods fail

  • For immunofluorescence or flow cytometry, compare paraformaldehyde, methanol, and acetone fixation

  • Consider mild fixation (0.5-2% PFA) for shorter periods when working with membrane proteins

How can I optimize STEAP3 antibody performance in challenging samples like tissue microarrays or FFPE tissues?

For difficult sample types:

• Antigen retrieval optimization:

  • Compare heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 8.0-9.0)

    • Tris-EDTA (pH 9.0)

  • Test different retrieval times (10-30 minutes)

  • Consider using pressure cooker vs. microwave methods

• Signal amplification strategies:

  • Implement tyramide signal amplification (TSA)

  • Use polymer-based detection systems

  • Consider biotin-free detection methods to avoid endogenous biotin interference

  • Extend primary antibody incubation time (overnight at 4°C)

• Background reduction techniques:

  • Include additional blocking steps (avidin/biotin block, protein block)

  • Use specialized blockers for tissue-specific endogenous enzymes

  • Optimize washing steps (increase number, duration, or detergent concentration)

  • Consider using specialized buffers designed for reduction of background

• Validation approach for archived tissues:

  • Use matched fresh and fixed samples from the same source when possible

  • Include known positive controls (tissues with confirmed high STEAP3 expression)

  • Consider dual markers to confirm specificity of staining pattern

  • Quantify staining using digital pathology tools for more objective assessment

How can STEAP3 antibodies be used to study its role as a prognostic biomarker in glioblastoma and other cancers?

Recent research has highlighted STEAP3's potential as a prognostic biomarker :

What are the considerations for developing STEAP3-targeted therapeutic antibodies based on current research?

Though primarily a research focus currently, STEAP3-targeted therapeutics present interesting possibilities:

• Target validation requirements:

  • Confirm STEAP3's role in disease progression through multiple knockdown/knockout models

  • Validate that targeting STEAP3 produces the desired phenotype (reduced tumor growth, improved cardiac function, etc.)

  • Determine potential off-target effects by detailed understanding of STEAP3 expression in normal tissues

• Antibody format selection considerations:

  • Evaluate conventional antibodies vs. alternative formats (bispecific, antibody-drug conjugates)

  • For membrane-expressed STEAP3, consider formats that can engage immune effector cells

  • For targeting nuclear STEAP3, explore cell-penetrating antibody formats or target the pathway indirectly

• Functional screening approach:

  • Test antibodies for their ability to:

    • Block protein-protein interactions (e.g., STEAP3-EGFR interaction)

    • Inhibit enzymatic activity (ferric-chelate reductase function)

    • Induce internalization and degradation of the target

    • Activate or inhibit specific signaling pathways

• Context-dependent targeting strategy:

  • In cancers where STEAP3 is pro-tumorigenic (like HCC), develop inhibitory antibodies

  • In cardiac hypertrophy, where STEAP3 is protective, explore agonistic approaches

  • Consider combination strategies that target related pathways (STAT3, RAC1-ERK)

How can computational approaches improve STEAP3 antibody design and customization for specific research needs?

Advanced computational methods offer new possibilities for antibody development:

• AI-driven design workflow:

  • Use computational modeling to predict antibody-epitope interactions

  • Apply machine learning approaches to optimize complementarity-determining regions (CDRs)

  • Design antibodies with customized specificity profiles for STEAP3 vs. other STEAP family members

  • Implement biophysics-informed modeling similar to approaches used for other antibodies

• Epitope mapping and optimization:

  • Use in silico analysis to identify optimal epitopes based on:

    • Surface accessibility

    • Conservation across species (for cross-reactivity)

    • Uniqueness compared to related proteins

    • Post-translational modification status

  • Design antibodies that can distinguish STEAP3 conformational states

• Specificity enhancement strategies:

  • Analyze binding modes associated with specific ligands or conformations

  • Optimize CDR sequences using controlled library generation and high-throughput screening

  • Refine antibody sequences to minimize off-target binding

  • Incorporate negative design principles to explicitly avoid unwanted cross-reactivity

• Validation experimentation design:

  • Create diverse test panels to validate computational predictions

  • Employ multiple orthogonal methods to confirm binding properties

  • Iteratively refine computational models based on experimental feedback

  • Validate across multiple applications to ensure versatility